Cipla’s South Africa arm to acquire 30% in Brandmed

PTI New Delhi | Updated on April 16, 2019 Published on April 16, 2019

Drug major Cipla on Tuesday said its South Africa-based subsidiary will acquire 30 per cent stake in the connected healthcare firm Brandmed (Pty) Ltd for an upfront cash consideration of ZAR 65 million (nearly ₹ 32 crore).

Cipla Medpro, South Africa’s third-largest pharmaceutical company in the private sector, will also pay certain milestone payment for the stake acquisition over a period of three years, subject to meeting agreed profit targets.

“This transaction will help to transition healthcare from being reactive to a proactive and real-time monitoring model that focuses on promoting wellness instead of managing illness,” Cipla Medpro Chief Executive Officer Paul Miller said in a statement.

By pairing the company’s strengths with Brandmed’s innovative, patient-centric approach in healthcare, Cipla Medpro will enhance its diverse portfolio in the NCD area to provide holistic care to patients from awareness to disease management, thereby enabling patient adherence and compliance, he added.

Brandmed, founded in 2014, has developed a fully integrated end-to-end solution to address outcomes and value-based care for patients with chronic lifestyle and non-communicable diseases (NCDs) such as hypertension, diabetes, high cholesterol, asthma and chronic obstructive pulmonary disease.

Cipla shares on Tuesday fell 1.20 per cent to ₹ 559.30 apiece on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on April 16, 2019
This article is closed for comments.
Please Email the Editor